GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (STU:6LJ) » Definitions » EV-to-EBITDA

Matinas BioPharma Holdings (STU:6LJ) EV-to-EBITDA : -1.43 (As of Jun. 19, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Matinas BioPharma Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Matinas BioPharma Holdings's enterprise value is €30.64 Mil. Matinas BioPharma Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-21.38 Mil. Therefore, Matinas BioPharma Holdings's EV-to-EBITDA for today is -1.43.

The historical rank and industry rank for Matinas BioPharma Holdings's EV-to-EBITDA or its related term are showing as below:

STU:6LJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.88   Med: -4.65   Max: -0.44
Current: -1.42

During the past 11 years, the highest EV-to-EBITDA of Matinas BioPharma Holdings was -0.44. The lowest was -24.88. And the median was -4.65.

STU:6LJ's EV-to-EBITDA is ranked worse than
100% of 456 companies
in the Biotechnology industry
Industry Median: 8.71 vs STU:6LJ: -1.42

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-19), Matinas BioPharma Holdings's stock price is €0.132. Matinas BioPharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.112. Therefore, Matinas BioPharma Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Matinas BioPharma Holdings EV-to-EBITDA Historical Data

The historical data trend for Matinas BioPharma Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings EV-to-EBITDA Chart

Matinas BioPharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.34 -9.43 -7.24 -3.55 -1.61

Matinas BioPharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.77 -2.74 -0.61 -1.61 -2.34

Competitive Comparison of Matinas BioPharma Holdings's EV-to-EBITDA

For the Biotechnology subindustry, Matinas BioPharma Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's EV-to-EBITDA falls into.



Matinas BioPharma Holdings EV-to-EBITDA Calculation

Matinas BioPharma Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=30.643/-21.381
=-1.43

Matinas BioPharma Holdings's current Enterprise Value is €30.64 Mil.
Matinas BioPharma Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-21.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Matinas BioPharma Holdings  (STU:6LJ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Matinas BioPharma Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.132/-0.112
=At Loss

Matinas BioPharma Holdings's share price for today is €0.132.
Matinas BioPharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.112.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Matinas BioPharma Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings (STU:6LJ) Business Description

Traded in Other Exchanges
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.

Matinas BioPharma Holdings (STU:6LJ) Headlines

No Headlines